MA46973A - Polymorphes de sépiaptérine et leurs sels - Google Patents
Polymorphes de sépiaptérine et leurs selsInfo
- Publication number
- MA46973A MA46973A MA046973A MA46973A MA46973A MA 46973 A MA46973 A MA 46973A MA 046973 A MA046973 A MA 046973A MA 46973 A MA46973 A MA 46973A MA 46973 A MA46973 A MA 46973A
- Authority
- MA
- Morocco
- Prior art keywords
- sepiapterin
- polymorphs
- salts
- sepiapterin polymorphs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427686P | 2016-11-29 | 2016-11-29 | |
| US201762546390P | 2017-08-16 | 2017-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46973A true MA46973A (fr) | 2019-10-09 |
Family
ID=62241930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046973A MA46973A (fr) | 2016-11-29 | 2017-11-28 | Polymorphes de sépiaptérine et leurs sels |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11072614B2 (enExample) |
| EP (1) | EP3548497A4 (enExample) |
| JP (3) | JP7148533B2 (enExample) |
| KR (3) | KR102561697B1 (enExample) |
| CN (2) | CN116903624A (enExample) |
| AU (3) | AU2017366879C1 (enExample) |
| BR (1) | BR122021026889A8 (enExample) |
| CA (1) | CA3043502A1 (enExample) |
| CO (1) | CO2019006018A2 (enExample) |
| IL (2) | IL266955B2 (enExample) |
| MA (1) | MA46973A (enExample) |
| MX (3) | MX386520B (enExample) |
| NZ (1) | NZ753504A (enExample) |
| WO (1) | WO2018102315A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130197000A1 (en) | 2010-04-22 | 2013-08-01 | Nihon University | Drug and food/drink for preventing or improving cerebral dysfunction |
| WO2018102314A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymorphic form of sepiapterin |
| IL266955B2 (en) | 2016-11-29 | 2023-09-01 | Ptc Therapeutics Mp Inc | Polymorphs of spiafatrin and its salts |
| WO2019046849A1 (en) | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
| SMT202400430T1 (it) | 2018-05-30 | 2024-11-15 | Ptc Therapeutics Mp Inc | Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina |
| EP3801534A4 (en) | 2018-05-30 | 2022-03-16 | PTC Therapeutics MP, Inc. | COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE |
| CA3102070A1 (en) | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| ES2994060T3 (en) | 2019-08-05 | 2025-01-16 | Ptc Therapeutics Mp Inc | Use of sepiapterin and metabolites thereof to treat radiation exposure |
| KR20220070477A (ko) * | 2019-09-25 | 2022-05-31 | 피티씨 테라퓨틱스 엠피, 인크. | 고페닐알라닌혈증 치료 방법 |
| AU2021209935A1 (en) | 2020-01-24 | 2022-08-18 | Ptc Therapeutics Mp, Inc. | Methods for treating Parkinson's disease with sepiapterin |
| JP2024506336A (ja) | 2021-02-09 | 2024-02-13 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | 膠芽腫の治療方法 |
| WO2022173823A1 (en) | 2021-02-09 | 2022-08-18 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
| WO2023055923A1 (en) | 2021-09-29 | 2023-04-06 | Ptc Therapeutics, Inc. | Pharmaceutical composition of sepiapterin |
| WO2024249602A2 (en) * | 2023-05-30 | 2024-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Restless leg syndrome (rls) and periodic leg movements (plms) during sleep: biomarker and drug target |
| CN117205164B (zh) * | 2023-09-30 | 2024-07-26 | 山东新时代药业有限公司 | 一种盐酸沙丙蝶呤片剂及其制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| ES2177654T3 (es) | 1994-08-05 | 2002-12-16 | Suntory Ltd | Remedio contra la degeneracion espinocerebelosa. |
| EP0854934A4 (en) | 1995-08-18 | 2000-09-06 | Donald W Landry | DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| WO2005041975A1 (en) | 2003-10-31 | 2005-05-12 | Altana Pharma Ag | Use of bh4 for the treatment of respiratory diseases |
| JP2007536210A (ja) | 2003-11-17 | 2007-12-13 | メルック・エプロバ・アクチエンゲゼルシヤフト | （６ｒ）−ｌ−エリスロ−テトラヒドロビオプテリンジヒドロクロライドの結晶形 |
| HUE029533T2 (en) | 2003-11-17 | 2017-03-28 | Biomarin Pharm Inc | Treatment of phenylketonuria with BH4 |
| AU2004290692A1 (en) | 2003-11-17 | 2005-06-02 | Biomarin Pharmaceutical Inc. | Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin |
| EP2436379A1 (en) | 2004-11-17 | 2012-04-04 | BioMarin Pharmaceutical Inc. | Stable tablet formulation |
| EP1819340A2 (en) * | 2004-12-08 | 2007-08-22 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| WO2006118322A1 (en) | 2005-04-28 | 2006-11-09 | Shiratori Pharmaceutical Co., Ltd. | Method for producing hydrazone derivatives |
| US20080075666A1 (en) | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| DK3461503T3 (da) * | 2007-04-11 | 2022-02-14 | Biomarin Pharm Inc | Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder |
| NZ588379A (en) * | 2008-03-10 | 2012-07-27 | Takeda Pharmaceutical | Crystal of benzimidazole compound |
| ES2736730T3 (es) | 2008-08-12 | 2020-01-07 | Orpha Swiss Gmbh | Forma de administración farmacéutica que contiene tetrahidrobiopterina |
| AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
| MX2012002179A (es) | 2009-08-20 | 2012-03-16 | Novartis Ag | Compuestos heterociclicos de oxima. |
| US20130197000A1 (en) | 2010-04-22 | 2013-08-01 | Nihon University | Drug and food/drink for preventing or improving cerebral dysfunction |
| US9884909B2 (en) * | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| EP2680848A4 (en) | 2011-03-01 | 2014-11-05 | Rubicon Res Private Ltd | STABLE TETRAHYDROBIOPTERINE COMPOSITIONS |
| US9216178B2 (en) * | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| ES2681345T3 (es) * | 2012-05-07 | 2018-09-12 | Shiratori Pharmaceutical Co., Ltd. | Método para producir sepiapterina y tetrahidrolactoilpterina |
| AU2017286544B2 (en) | 2016-06-13 | 2022-10-20 | Meharry Medical College | Modulation of the nitric oxide synthase pathway for oral health |
| JP2019527242A (ja) | 2016-07-29 | 2019-09-26 | ディファーマ エッセ．ア． | サプロプテリンジヒドロクロリドを含む医薬組成物キット |
| IL266955B2 (en) | 2016-11-29 | 2023-09-01 | Ptc Therapeutics Mp Inc | Polymorphs of spiafatrin and its salts |
| WO2018102314A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymorphic form of sepiapterin |
| TWI765936B (zh) | 2016-11-29 | 2022-06-01 | 美商東京威力科創Ｆｓｉ股份有限公司 | 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭 |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2019046849A1 (en) | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
| CA3102070A1 (en) | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| EP3801534A4 (en) | 2018-05-30 | 2022-03-16 | PTC Therapeutics MP, Inc. | COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE |
| SMT202400430T1 (it) | 2018-05-30 | 2024-11-15 | Ptc Therapeutics Mp Inc | Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina |
| ES2994060T3 (en) | 2019-08-05 | 2025-01-16 | Ptc Therapeutics Mp Inc | Use of sepiapterin and metabolites thereof to treat radiation exposure |
| KR20220070477A (ko) | 2019-09-25 | 2022-05-31 | 피티씨 테라퓨틱스 엠피, 인크. | 고페닐알라닌혈증 치료 방법 |
-
2017
- 2017-11-28 IL IL266955A patent/IL266955B2/en unknown
- 2017-11-28 AU AU2017366879A patent/AU2017366879C1/en active Active
- 2017-11-28 KR KR1020197015403A patent/KR102561697B1/ko active Active
- 2017-11-28 MA MA046973A patent/MA46973A/fr unknown
- 2017-11-28 CN CN202310843616.4A patent/CN116903624A/zh active Pending
- 2017-11-28 KR KR1020237025450A patent/KR102789662B1/ko active Active
- 2017-11-28 KR KR1020257010115A patent/KR20250051124A/ko active Pending
- 2017-11-28 EP EP17876202.7A patent/EP3548497A4/en active Pending
- 2017-11-28 WO PCT/US2017/063517 patent/WO2018102315A1/en not_active Ceased
- 2017-11-28 MX MX2019006206A patent/MX386520B/es unknown
- 2017-11-28 BR BR122021026889A patent/BR122021026889A8/pt not_active Application Discontinuation
- 2017-11-28 CA CA3043502A patent/CA3043502A1/en active Pending
- 2017-11-28 NZ NZ753504A patent/NZ753504A/en unknown
- 2017-11-28 US US16/464,771 patent/US11072614B2/en active Active
- 2017-11-28 CN CN201780084821.XA patent/CN110248948B/zh active Active
- 2017-11-28 JP JP2019548534A patent/JP7148533B2/ja active Active
- 2017-11-28 IL IL301470A patent/IL301470A/en unknown
-
2019
- 2019-05-28 MX MX2021011683A patent/MX2021011683A/es unknown
- 2019-05-28 MX MX2021011676A patent/MX2021011676A/es unknown
- 2019-06-10 CO CONC2019/0006018A patent/CO2019006018A2/es unknown
-
2021
- 2021-06-09 US US17/342,910 patent/US11773097B2/en active Active
-
2022
- 2022-05-23 AU AU2022203481A patent/AU2022203481B2/en active Active
- 2022-09-22 JP JP2022151886A patent/JP2023002532A/ja active Pending
-
2023
- 2023-08-21 US US18/236,095 patent/US12269829B2/en active Active
-
2024
- 2024-01-18 AU AU2024200344A patent/AU2024200344B2/en active Active
- 2024-05-30 JP JP2024087740A patent/JP2024123011A/ja active Pending
-
2025
- 2025-01-15 US US19/021,475 patent/US20250230164A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284874A (en) | Valbenazine salts and polymorphs thereof | |
| MA46973A (fr) | Polymorphes de sépiaptérine et leurs sels | |
| IL265166B (en) | Anti-influenza virus pyrimidine derivatives | |
| EP3487448A4 (en) | EXPANDABLE IMPLANT | |
| MA54910A (fr) | Sels de pyridine et procédé | |
| DK3558961T3 (da) | Polymorfer | |
| DK3558995T3 (da) | Polymorfer | |
| LT3402792T (lt) | Chinolin-2-ono dariniai | |
| LT3457851T (lt) | Sobetiromo dariniai | |
| EP3564216A4 (en) | PYRIMIDINE DERIVATIVE | |
| EP3383883A4 (en) | SALTS OF CONJUGATES TO CANCER THERAPY | |
| DK3286260T3 (da) | Polyolefinrør | |
| PT3247711T (pt) | Novos sais e polimorfos de scy-078 | |
| DK3372589T3 (da) | Pyrimidinderivat | |
| DE102016006280A8 (de) | Flächengebilde | |
| DK3380465T3 (da) | Diaminopyridinderivativer | |
| EP3546539A4 (en) | ROLL-SHAPED BODY | |
| EP3470085A4 (en) | BIOKOMPATIBLE PERITONEAL DIALYSIS | |
| MA50669A (fr) | Nouveaux sels | |
| EP3368527A4 (en) | Palbociclib salts | |
| FIC20170055I1 (fi) | Nusinerseeni tai sen suolat | |
| IL258458B (en) | Peroxyhemiacetal profragrant and proflavor compounds | |
| DE112017003625A5 (de) | Difluorstilben-Derivate | |
| FR3050606B1 (fr) | Sillonneuse droite triangulaire isocele | |
| ITUA20162617A1 (it) | Avvolgibile |